Intracystic evaluation of tumor markers in benign and malignant ovarian pathology

Objective: To evaluate, in patients with benign and malignant ovarian cysts, serum samples and ovarian intracystic fluids for the presence of tumor markers such as CA 125, CA 15.3, tissue polypeptide antigen (TPA), CA 19.9 and the carcinoembryonic antigen (CEA).

Material and method: We studied overall 64 patients with ovarian pathology. Sixteen patients were affected by functional cysts, 28 women by benign cystic tumors and 20 by cystoadenocarcinomas.

Results: Average serum levels of all but CA 15.3, TPA and CEA tumor markers of benign cystic ovarian tumors were higher than those of functional cysts. All but CA 19.9 mean intracystic fluid markers levels were more elevated in benign tumors than in functional cysts. In patients with malignant cystic tumors, all but CEA mean serum marker levels were higher than those of benign tumors; furthermore even all mean intracystic levels of markers were more elevated than those of benign tumors.

Conclusion: This study confirmed the high positivity of tumor markers such as CA 125, CA 15.3, TPA, CA 19.9 and CEA in both the serum and intracystic fluid of patients with malignant epithelial ovarian tumors.

Cystic ovarian pathology; CA 125, CA 15.3, TPA, CA I 9.9 and CEA; serum and intracystic fluid evaluation

[1] Kudoh K., Kikuchi Y., Kita T., Tode T., Takano M., Hirata J. et al.: "Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma". Gynecol. Obstet. Invest., 1999, 47, 52.

[2] Bast R. C., Klug T. L., St. John E., Jenison E., Niloff J. M., Lazarus H. et al.: "A radioimmunoassay using monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med., 1983, 309, 883.

[3] Jacobs I., Bast R. C.: "The CA 125 tumor-associated antigen: a review of the literature". Hum. Reprod., 1989, 4, 1.

[4] Kenemans P., Bast R. C., Ydema C. A., Price M. R., Hilgers J.: "CA 125 and polymorphic epithelial mucin as serum tumor markers". Cancer Rev., 1988, 11, 119.

[5] De Bruijn H. W. A., Ten Hoor K. A., Boonstra H., Marrink J., Krans M., Aalders J. G.: "Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids". Tumor Biol., 1993, 14, 105.

[6] Gadducci A., Ferdeghini M., Prontera C., Moretti I., Maraini C., Bianchi R. et al.: "The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis". Gynecol. Oncol., 1992, 44, 147.

[7] Pittway D. E., Fayez J. A., Douglas J. W.: "Serum CA-125 in the evaluation of benign adnexal cysts". Am. J. Obstet. Gynecol., 1987, 157, 1426.

[8] O'Shaughnessy A., Check J. H., Nowroozi K., Lurie D.: "CA 125 levels measured in different phases of the menstrual cycle in screening for endometriosis". Obstet. Gynecol., 1993, 81, 89.

[9] FIGO stages: "1988 revision". Gynecol. Obstet., 1989, 35, 125.

[10] Sassone A. M., Timor-Tritsch I. E., Artner A., Westhoff C., Warren W.B.: "Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy". Obstet. Gynecol., 1991, 78, 70.

[11] Weiner Z., Thaler I., Beck D., Rottem S., Deutsch M., Brandes J. M.: "Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging". Obstet. Gynecol., 1992, 79, 159.

[12] Daunter B. "Tumor markers in gynecologic oncology". Gynecol. Oncol., 1990, 39, 1.

[13] Menczer J., Ben-Baruch G., Moran 0., Lipitz S.: "Cyst fluid CA 125 levels in ovarian epithelial neoplasms". Obstet. Gynecol., 1993, 81, 25.

[14] Gaetje R., Popp L. W.: "Is differentation of benign and malignant cystic adnexal masses possible by evaluation of cysts fluids with respect to color, cytology, steroid hormones and tumor markers?". Acta Obstet. Gynecol. Scand., 1994, 73, 502.

[15] Harlozinska A., Bar J. K., Gawlikowski W., Richter R., Cislo M.: "CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms". Ann. Chirurgiae Gynaecologiae, 1991, 80, 368.

[16] Fleuren G. J., Nap M., Aalders J. G., Trimbos J. B., DeBruijn H. W.: "Explanation of the limited correlation between tumor CA-125 content and serum CA-125 antigen levels in patients with ovarian tumors". Cancer, 1987, 60, 2437.

[17] Tabuchi Y., Deguchi H., Imanishi K., Saitoh Y.: "Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables." Cancer, 1987, 59, 1283.

[18] Pinto M. M., Bernstein L. H., Brogan D. A.: "Measurements of CA-125, carcino-embryonic antigen and alphafetoprotein in ovarian cyst fluids: diagnostic adjunct to cytology." Acta Cytol., 1988, 32, 747.

[19] Mezger J., Permanetter W., Gerbes A. L., Wilmanns W., Lamerz R. : "Tumour associated antigens in diagnosis of serous effusions". J. Clin. Pathol., 1988, 41, 633.